Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803f1a2487b4-trace').style.display = (document.getElementById('cakeErr6803f1a2487b4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6803f1a2487b4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803f1a2487b4-code').style.display = (document.getElementById('cakeErr6803f1a2487b4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803f1a2487b4-context').style.display = (document.getElementById('cakeErr6803f1a2487b4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6803f1a2487b4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6803f1a2487b4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26757,
		&#039;title&#039; =&gt; &#039;Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 December, 2014, http://www.thehindu.com/business/Industry/generic-drug-makers-get-a-boost-from-sc-ruling/article6689370.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674800,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26757,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Access to Medicines,patent,patents,medicines,Supreme Court,generic drugs,generic medicine,generic medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt; In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26757,
	&#039;title&#039; =&gt; &#039;Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 December, 2014, http://www.thehindu.com/business/Industry/generic-drug-makers-get-a-boost-from-sc-ruling/article6689370.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674800,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {},
		(int) 9 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26757
$metaTitle = &#039;LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Access to Medicines,patent,patents,medicines,Supreme Court,generic drugs,generic medicine,generic medicines&#039;
$metaDesc = &#039;
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt; In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu | Im4change.org</title>
    <meta name="description" content="
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Generic drug makers get a boost from SC ruling -Ramnath Subbu</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"> In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.</p><p align="justify">Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.</p><p align="justify">Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer's selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.</p><p align="justify">&quot;It is a landmark decision in the patent history of India,'' was how a senior industry source described the decision.</p><p align="justify">&quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,'' a spokesperson from Natco told this correspondent.</p><p align="justify">Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.</p><p align="justify">Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.''</p><p align="justify">&quot;Today, we applaud this heartening news, which reaffirms India's critical role in forging a new and progressive path in balancing intellectual property and public health,'' she said.</p><p align="justify">&quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,'' S. V. Veeramani, President, Indian Drug Manufacturers' Association (IDMA), said.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803f1a2487b4-trace').style.display = (document.getElementById('cakeErr6803f1a2487b4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6803f1a2487b4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803f1a2487b4-code').style.display = (document.getElementById('cakeErr6803f1a2487b4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803f1a2487b4-context').style.display = (document.getElementById('cakeErr6803f1a2487b4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6803f1a2487b4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6803f1a2487b4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26757,
		&#039;title&#039; =&gt; &#039;Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 December, 2014, http://www.thehindu.com/business/Industry/generic-drug-makers-get-a-boost-from-sc-ruling/article6689370.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674800,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26757,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Access to Medicines,patent,patents,medicines,Supreme Court,generic drugs,generic medicine,generic medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt; In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26757,
	&#039;title&#039; =&gt; &#039;Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 December, 2014, http://www.thehindu.com/business/Industry/generic-drug-makers-get-a-boost-from-sc-ruling/article6689370.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674800,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {},
		(int) 9 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26757
$metaTitle = &#039;LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Access to Medicines,patent,patents,medicines,Supreme Court,generic drugs,generic medicine,generic medicines&#039;
$metaDesc = &#039;
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt; In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu | Im4change.org</title>
    <meta name="description" content="
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Generic drug makers get a boost from SC ruling -Ramnath Subbu</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"> In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.</p><p align="justify">Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.</p><p align="justify">Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer's selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.</p><p align="justify">&quot;It is a landmark decision in the patent history of India,'' was how a senior industry source described the decision.</p><p align="justify">&quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,'' a spokesperson from Natco told this correspondent.</p><p align="justify">Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.</p><p align="justify">Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.''</p><p align="justify">&quot;Today, we applaud this heartening news, which reaffirms India's critical role in forging a new and progressive path in balancing intellectual property and public health,'' she said.</p><p align="justify">&quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,'' S. V. Veeramani, President, Indian Drug Manufacturers' Association (IDMA), said.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803f1a2487b4-trace').style.display = (document.getElementById('cakeErr6803f1a2487b4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6803f1a2487b4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803f1a2487b4-code').style.display = (document.getElementById('cakeErr6803f1a2487b4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803f1a2487b4-context').style.display = (document.getElementById('cakeErr6803f1a2487b4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6803f1a2487b4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6803f1a2487b4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26757,
		&#039;title&#039; =&gt; &#039;Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 December, 2014, http://www.thehindu.com/business/Industry/generic-drug-makers-get-a-boost-from-sc-ruling/article6689370.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674800,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26757,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Access to Medicines,patent,patents,medicines,Supreme Court,generic drugs,generic medicine,generic medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt; In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26757,
	&#039;title&#039; =&gt; &#039;Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 December, 2014, http://www.thehindu.com/business/Industry/generic-drug-makers-get-a-boost-from-sc-ruling/article6689370.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674800,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {},
		(int) 9 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26757
$metaTitle = &#039;LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Access to Medicines,patent,patents,medicines,Supreme Court,generic drugs,generic medicine,generic medicines&#039;
$metaDesc = &#039;
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt; In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer&#039;s appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer&#039;s selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is a landmark decision in the patent history of India,&#039;&#039; was how a senior industry source described the decision.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,&#039;&#039; a spokesperson from Natco told this correspondent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &amp;quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.&#039;&#039;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Today, we applaud this heartening news, which reaffirms India&#039;s critical role in forging a new and progressive path in balancing intellectual property and public health,&#039;&#039; she said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,&#039;&#039; S. V. Veeramani, President, Indian Drug Manufacturers&#039; Association (IDMA), said.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu | Im4change.org</title>
    <meta name="description" content="
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Generic drug makers get a boost from SC ruling -Ramnath Subbu</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify"> In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.</p><p align="justify">Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.</p><p align="justify">Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer's selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.</p><p align="justify">&quot;It is a landmark decision in the patent history of India,'' was how a senior industry source described the decision.</p><p align="justify">&quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,'' a spokesperson from Natco told this correspondent.</p><p align="justify">Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.</p><p align="justify">Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.''</p><p align="justify">&quot;Today, we applaud this heartening news, which reaffirms India's critical role in forging a new and progressive path in balancing intellectual property and public health,'' she said.</p><p align="justify">&quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,'' S. V. Veeramani, President, Indian Drug Manufacturers' Association (IDMA), said.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 26757,
		'title' => 'Generic drug makers get a boost from SC ruling -Ramnath Subbu',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.
</p>
<p align="justify">
Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.
</p>
<p align="justify">
Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer's selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.
</p>
<p align="justify">
&quot;It is a landmark decision in the patent history of India,'' was how a senior industry source described the decision.
</p>
<p align="justify">
&quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,'' a spokesperson from Natco told this correspondent.
</p>
<p align="justify">
Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.
</p>
<p align="justify">
Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.''
</p>
<p align="justify">
&quot;Today, we applaud this heartening news, which reaffirms India's critical role in forging a new and progressive path in balancing intellectual property and public health,'' she said.
</p>
<p align="justify">
&quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,'' S. V. Veeramani, President, Indian Drug Manufacturers' Association (IDMA), said.
</p>',
		'credit_writer' => 'The Hindu, 13 December, 2014, http://www.thehindu.com/business/Industry/generic-drug-makers-get-a-boost-from-sc-ruling/article6689370.ece?homepage=true',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4674800,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 26757,
	'metaTitle' => 'LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu',
	'metaKeywords' => 'Access to Health,Access to Healthcare,Access to Medicines,patent,patents,medicines,Supreme Court,generic drugs,generic medicine,generic medicines',
	'metaDesc' => '
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco...',
	'disp' => '<div align="justify">-The Hindu</div><p align="justify"> In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.</p><p align="justify">Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.</p><p align="justify">Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer's selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.</p><p align="justify">&quot;It is a landmark decision in the patent history of India,'' was how a senior industry source described the decision.</p><p align="justify">&quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,'' a spokesperson from Natco told this correspondent.</p><p align="justify">Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.</p><p align="justify">Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.''</p><p align="justify">&quot;Today, we applaud this heartening news, which reaffirms India's critical role in forging a new and progressive path in balancing intellectual property and public health,'' she said.</p><p align="justify">&quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,'' S. V. Veeramani, President, Indian Drug Manufacturers' Association (IDMA), said.</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 26757,
	'title' => 'Generic drug makers get a boost from SC ruling -Ramnath Subbu',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.
</p>
<p align="justify">
Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.
</p>
<p align="justify">
Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer's selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.
</p>
<p align="justify">
&quot;It is a landmark decision in the patent history of India,'' was how a senior industry source described the decision.
</p>
<p align="justify">
&quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,'' a spokesperson from Natco told this correspondent.
</p>
<p align="justify">
Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.
</p>
<p align="justify">
Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.''
</p>
<p align="justify">
&quot;Today, we applaud this heartening news, which reaffirms India's critical role in forging a new and progressive path in balancing intellectual property and public health,'' she said.
</p>
<p align="justify">
&quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,'' S. V. Veeramani, President, Indian Drug Manufacturers' Association (IDMA), said.
</p>',
	'credit_writer' => 'The Hindu, 13 December, 2014, http://www.thehindu.com/business/Industry/generic-drug-makers-get-a-boost-from-sc-ruling/article6689370.ece?homepage=true',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'generic-drug-makers-get-a-boost-from-sc-ruling-ramnath-subbu-4674800',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4674800,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {},
		(int) 8 => object(Cake\ORM\Entity) {},
		(int) 9 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 26757
$metaTitle = 'LATEST NEWS UPDATES | Generic drug makers get a boost from SC ruling -Ramnath Subbu'
$metaKeywords = 'Access to Health,Access to Healthcare,Access to Medicines,patent,patents,medicines,Supreme Court,generic drugs,generic medicine,generic medicines'
$metaDesc = '
-The Hindu


 In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco...'
$disp = '<div align="justify">-The Hindu</div><p align="justify"> In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals.</p><p align="justify">Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer.</p><p align="justify">Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer's selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully.</p><p align="justify">&quot;It is a landmark decision in the patent history of India,'' was how a senior industry source described the decision.</p><p align="justify">&quot;It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,'' a spokesperson from Natco told this correspondent.</p><p align="justify">Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said.</p><p align="justify">Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, &quot;MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.''</p><p align="justify">&quot;Today, we applaud this heartening news, which reaffirms India's critical role in forging a new and progressive path in balancing intellectual property and public health,'' she said.</p><p align="justify">&quot;The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,'' S. V. Veeramani, President, Indian Drug Manufacturers' Association (IDMA), said.</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Generic drug makers get a boost from SC ruling -Ramnath Subbu

-The Hindu In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals. Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the price at which it was sold by the patent holder, Bayer. Since 2012, Natco has been selling the drug at Rs.8,880 a pack of 120 against Bayer's selling price of Rs.2.84 lakh. Natco pays Bayer a royalty fee. Bayer has challenged the order before the Intellectual Property Appellate Board (IPAB) and then the Bombay High Court unsuccessfully. "It is a landmark decision in the patent history of India,'' was how a senior industry source described the decision. "It vindicates the stand taken by us keeping in mind the low per capita income levels in the country. The intention is to have wide reach, accessibility and affordability for medicines,'' a spokesperson from Natco told this correspondent. Since 2012, Natco treated more than 20,000 cancer patients with the drug, of which 2,000 were treated free of cost, the spokesperson said. Leena Menghaney, Regional Head (South Asia), MSF Access Campaign, said, "MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.'' "Today, we applaud this heartening news, which reaffirms India's critical role in forging a new and progressive path in balancing intellectual property and public health,'' she said. "The development will act as a fillip for generic manufacturers and encourage manufacture of affordable drugs to increase accessibility. Being the first and only CL granted by the government to date, it is definitely a positive development for Indian generic drug manufacturers,'' S. V. Veeramani, President, Indian Drug Manufacturers' Association (IDMA), said.